# Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies

**Authors:** Godfrey A. Dzhivhuho, Patrick E. H. Jackson, Ethan S. Honeycutt, Flavio da Silva Mesquita, Jing Huang, Marie-Louise Hammarskjold, David Rekosh

PMC · DOI: 10.1371/journal.ppat.1012885 · PLOS Pathogens · 2025-05-15

## TL;DR

This study shows how the HIV-1 Rev-RRE system affects virus replication and reactivation from latency, suggesting that boosting this system could help cure HIV.

## Contribution

The study reveals how variations in Rev-RRE activity influence HIV replication and latency reactivation, offering new insights for cure strategies.

## Key findings

- Higher Rev-RRE activity increases HIV-1 replication capacity while maintaining Nef expression.
- Viruses with low Rev activity can acquire mutations to boost Rev-RRE activity and replication.
- Low Rev-RRE activity proviruses are harder to reactivate from latency, complicating cure strategies.

## Abstract

The HIV-1 Rev-RRE regulatory axis plays a crucial role in viral replication by facilitating the nucleo-cytoplasmic export and expression of viral mRNAs with retained introns. In this study, we investigated the impact of variation in Rev-RRE functional activity on HIV-1 replication kinetics and reactivation from latency. Using a novel HIV-1 viral vector with an interchangeable Rev cassette, we engineered viruses with two diverse Rev functional activities and demonstrated that higher Rev-RRE activity confers greater viral replication capacity while maintaining a constant level of Nef expression. In addition, a low Rev activity virus rapidly acquired a compensatory mutation in the RRE that significantly increased Rev-RRE activity and replication. In a latency model, proviruses with differing Rev-RRE activity levels varied in the efficiency of viral reactivation, affecting both initial viral release and subsequent replication kinetics. These results demonstrate that activity differences in the Rev-RRE axis among different viral isolates have important implications for HIV replication dynamics and persistence. Importantly, our findings indicate that bolstering Rev/RRE activity could be explored as part of latency reversal strategies in HIV cure efforts.

The activity of the HIV-1 Rev-RRE axis is essential for viral replication and varies among primary viral isolates. However, the role of this for viral fitness, evolution, and persistence has not previously been investigated. Our results show that during in vitro replication, there is a selective fitness advantage for a virus with higher Rev-RRE activity and that HIV has the ability to fine-tune this regulatory system with minimal sequence changes. Additionally, the maintenance of Nef expression in a low Rev activity virus suggests a potential mechanism for balancing immune evasion and replication capacity in different selection landscapes within a host. We also show that the virus with low Rev-RRE activity was more difficult to reverse from latency than the virus with higher Rev-RRE activity. Thus, differences in provirus Rev-RRE activity may be a barrier to developing effective latency reversal strategies. These findings provide new insights into the complex roles the Rev/RRE axis plays in functionality, viral fitness, evolution, and persistence.

## Linked entities

- **Genes:** Rev (Revolute) [NCBI Gene 45924], S100B (S100 calcium binding protein B) [NCBI Gene 6285]

## Full-text entities

- **Genes:** NXT1 (nuclear transport factor 2 like export factor 1) [NCBI Gene 29107] {aka MTR2, P15}, Rev [NCBI Gene 155908], RNF112 (ring finger protein 112) [NCBI Gene 7732] {aka BFP, ZNF179}, LBR (lamin B receptor) [NCBI Gene 3930] {aka C14SR, DHCR14B, LMN2R, PHA, PHASK, TDRD18}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, NXF1 (nuclear RNA export factor 1) [NCBI Gene 10482] {aka MEX67, TAP}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, TAT (tyrosine aminotransferase) [NCBI Gene 6898], CCR5 (C-C motif chemokine receptor 5) [NCBI Gene 1234] {aka CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Nef [NCBI Gene 156110], SERINC3 (serine incorporator 3) [NCBI Gene 10955] {aka AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1}, TMED2 (transmembrane p24 trafficking protein 2) [NCBI Gene 10959] {aka P24A, RNP24, p24, p24b1, p24beta1}, XPO1 (exportin 1) [NCBI Gene 7514] {aka CRM-1, CRM1, emb, exp1}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, Env [NCBI Gene 155971], ERVK-6 (endogenous retrovirus group K member 6, envelope) [NCBI Gene 64006] {aka ERVK6, HERV-K(C7), HERV-K108, K-Rev, c-orf, cORF}, SERINC5 (serine incorporator 5) [NCBI Gene 256987] {aka C5orf12, TPO1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** AIDS (MESH:D000163), Infection (MESH:D007239), HIV (MESH:D015658)
- **Chemicals:** SDS (MESH:D012967), GlutaMAX (MESH:C054122), agarose (MESH:D012685), formaldehyde (MESH:D005557), Trypan Blue (MESH:D014343), EDTA (MESH:D004492), isopropanol (MESH:D019840), MgSO4 (MESH:D008278), AZT (MESH:D015215), DEAE-dextran (MESH:D003637), CO2 (MESH:D002245), 1X (-), PVDF (MESH:C024865), gentamicin (MESH:D005839), sodium chloride (MESH:D012965), Bis-Tris (MESH:C026272), glycogen (MESH:D006003), ethidium bromide (MESH:D004996), Ampicillin (MESH:D000667), ethanol (MESH:D000431), DMSO (MESH:D004121), MES (MESH:C004550), PBS (MESH:D007854)
- **Species:** Mason-Pfizer monkey virus (no rank) [taxon 11855], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676], Equine infectious anemia virus (no rank) [taxon 11665], Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C7214T, AUG to ACG, alanine to a valine, 7214T, serine to threonine change at amino acid position 70, A539V, L in 250
- **Cell lines:** pNL4-3 — Anopheles gambiae (African malaria mosquito), Spontaneously immortalized cell line (CVCL_Z622), NL4-3 — Neodiprion lecontei (Redheaded pine sawfly), Spontaneously immortalized cell line (CVCL_Z498), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), SupT1 — Homo sapiens (Human), Childhood T lymphoblastic lymphoma, Cancer cell line (CVCL_1714), HEK 293T/17 — Homo sapiens (Human), Transformed cell line (CVCL_1926)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12080775/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12080775/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC12080775/full.md

---
Source: https://tomesphere.com/paper/PMC12080775